Omeros Stock Today
| OMER Stock | USD 8.62 0.22 2.49% |
Performance11 of 100
| Odds Of DistressOver 53
|
Omeros is selling at 8.62 as of the 1st of February 2025; that is 2.49% down since the beginning of the trading day. The stock's lowest day price was 8.62. Omeros has 53 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 2nd of January 2025 and ending today, the 1st of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of October 2009 | Category Healthcare | Classification Health Care |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company has 57.95 M outstanding shares of which 9.27 M shares are now shorted by private and institutional investors with about 8.56 trading days to cover. More on Omeros
Moving against Omeros Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Omeros Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Catherine Melfi | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOmeros can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Omeros' financial leverage. It provides some insight into what part of Omeros' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Omeros (OMER) is traded on NASDAQ Exchange in USA. It is located in The Omeros Building, Seattle, WA, United States, 98119 and employs 198 people. Omeros is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 512.28 M. Omeros conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 57.95 M outstanding shares of which 9.27 M shares are now shorted by private and institutional investors with about 8.56 trading days to cover.
Omeros currently holds about 122.56 M in cash with 74.73 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.95.
Check Omeros Probability Of Bankruptcy
Ownership AllocationOmeros owns a total of 57.95 Million outstanding shares. 30% of Omeros outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Omeros Ownership Details
Omeros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-09-30 | 497 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 485 K | |
| Ubs Group Ag | 2024-09-30 | 450.1 K | |
| Nomura Holdings Inc | 2024-09-30 | 316.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 297.9 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 178.2 K | |
| Bank Of America Corp | 2024-09-30 | 176.3 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 161.3 K | |
| Susquehanna Fundamental Investments, Llc | 2024-06-30 | 156 K | |
| Ingalls & Snyder Llc | 2024-09-30 | 4.5 M | |
| Blackrock Inc | 2024-09-30 | 4.2 M |
Omeros Historical Income Statement
Omeros Stock Against Markets
Omeros Corporate Management
| Peter JD | General VP | Profile | |
| Nadia Dac | VP Officer | Profile | |
| Debra MT | Chief Officer | Profile | |
| David Ghesquiere | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Gregory MD | Chairman, CoFounder | Profile |
Additional Tools for Omeros Stock Analysis
When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.